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Abstract
Background: The aim of this study was to investigate the genetic diversity among Mycobacterium tuberculosis
complex circulating in patients with no known risk factors for multi-drug resistant (MDR) tuberculosis (TB) living in a
high MDR burden area and analyze the relationship between genotypes, primary drug resistance and age.
Methods: Samples were collected during January-July 2009. Isolates were tested for drug susceptibility to first-line
drugs and were genotyped by spoligotyping and the 15-loci Mycobacterial Interspersed Repetitive Unit (MIRU15).
Results: Among the 199 isolates analyzed, 169 (84.9%) were identified in the SpolDB4.0 and 30 (15.1%) could not
be matched to any lineage. The most prevalent lineage was Haarlem (29.6%), followed by T (15.6%), Beijing (14.1%),
Latin American Mediterranean (12.6%) and U (8.5%). A few isolates belonged to the X and S clades (4.5%).
Spoligotype analysis identified clustering among 148 of 169 isolates, whereas with MIRU15 all isolates were unique.
Out of 197 strains; 31.5% were resistant to at least one drug, 7.5% were MDR and 22.3% showed any resistance to
isoniazid.
Conclusion: In contrast with other Latin-American countries where LAM lineage is the most predominant, we
found the spoligotype 50 from the Haarlem lineage as the most common. None of the prevailing lineages showed
a significant association with age or resistance to isoniazid and/or rifampicin.
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Background
Tuberculosis (TB) currently holds the seventh place in
the global ranking of causes of death [1]. In 2010, there
were 8.8 million incident cases of TB or more than 24
000 per day [2]. Although Peru accounts for only 3% of
the population of the Americas 12% of the region’s TB
patients reside in Peru, and 32% of the multi drug resist-
ant (MDR) TB patients [3]. According to the Peruvian
National Tuberculosis Program, 17 264 new cases of
pulmonary TB were notified in Peru in 2010 [4]. Most
(58%) cases are notified in the capital; in particular in
the semi-urban districts in northern Lima, which repre-
sent 86% of the reported cases in the capital [5]. San
Juan de Lurigancho is the largest and most densely pop-
ulated district in Lima, with more than one million of
inhabitants, a TB incidence of 213/100,000 inhabitants
[6] and a primary MDR prevalence of 7% among all TB
cases [7]. Otero et al. found a high rate of primary
MDR-TB (6.3%) [8] in a population with no identifiable
risk factors for MDR-TB yet living in this high burden
area. It is not clear to what extent the emergence of
resistant TB in this low-risk population is due to the
clonal spread of a limited number of isolates or rather
following a random distribution. Also, predominance of
specific genotypes amongst younger inhabitants might
indicate recent introduction of this genotype in the
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population [9]. Molecular epidemiological methods
could help us to better understand TB population dy-
namics in Northern Lima, where antibiotic resistance
patterns have increased during recent years [10,11].
However, data on the molecular epidemiology of TB in
this country is limited; the SpolDB4.0 spoligotyping
database comprises only 96 Peruvian strains of the 39
609 published entries [12].
The aim of this study was to identify predominant cir-
culating TB lineages in this population with no known
risk factors for MDR-TB living in a hyper endemic
neighbourhood of Lima, and to investigate the relation-
ship between the genotypes, primary drug resistance pat-
terns and age.
Methods
Study setting and population
This study was embedded in a prospective cohort of
new cases of sputum smear-positive pulmonary TB,
conducted in a North Eastern district in the Lima
Province in Peru [12]. The district has 33 health centers
and one general hospital managed by the Ministry of
Health. All these health facilities provide TB treatment
and have laboratory facilities to screen TB suspects, such
as smear microscopy. For this study, sputum samples
were collected from sputum smear-positive pulmonary
TB subjects, previously untreated, >18 years, and with
no known risk factors for MDR-TB at 34 health facilities
[13], including the hospital of the district, between
January and July 2009.
Alcohol and drug abuse were considered high risk fac-
tors for MDR TB, in addition to the risk factors consid-
ered in the national guidelines: persons reporting
exposure to a MDR-TB case or to a TB case that failed
treatment or that died during treatment; patients with
immunosuppressive co-morbidities such as HIV and dia-
betes; persons working or admitted in a prison; health
care workers, and persons with a recent and prolonged
admission to a hospital. Patients with at least one of
these factors were excluded. All TB patients were treated
according to the National TB Guidelines [14] in line
with WHO treatment guidelines [15].
The district is geographically located on the slope of a
hill and it is informally divided in an upper- and lower
area. The upper area is poorer, with light construction
houses that typically lack basic necessities (light, water
and/or sanitation). The lower area is more urbanised;
houses are larger and made of cement.
Culture and drug-susceptibility testing
Sputum samples were transported to the Microbiology
Laboratory at the Institute of Tropical Medicine
(IMTAvH, Lima, Peru) within 6 hours of being pro-
duced. Samples were cultured on the same day or were
kept at 4°C when they arrived in the afternoon or during
the weekend. Smear microscopy following the Ziehl
Neelsen method was done, and then samples were cul-
tured on two slopes of Löwenstein-Jensen (LJ) medium,
following decontamination using the NalC-NaOH method.
The Mycobacterium tuberculosis (MTB) isolates were
tested for drug susceptibility (DST) using the 7H10 agar
method with the following drug concentrations: 0.2 μg/ml
and 1 μg/ml isoniazid (H), 1 μg/ml rifampicin (R), 2 μg/ml
streptomycin (S), and 6 μg/ml ethambutol (E).
Data collection methods
Data were collected at the health care facilities.
Researchers did not interfere with routine patient man-
agement. The trained and experienced field workers
interviewed the patient to obtain socio-demographic
data (name, sex, age), and determine MDR-TB risk fac-
tors to exclude patients from this study.
DNA isolation
To obtain genomic DNA for spoligotyping and MIRU-
VNTR typing, mycobacterial colonies grown on LJ
medium were resuspended in 100uL 1X Tris-EDTA buf-
fer (10 mM Tris-HCl, 1 mM Ethylenediaminetetracetic
acid disodium [pH8.0]) and then boiled for 30 minutes.
The suspension was centrifuged at 14 000 rpm for 10-
15 minutes to pellet cell debris. The supernatant
containing DNA was stored at -20°C and used in PCR
reactions.
Spoligotyping
Spoligotyping was performed using primers (DRa and
DRb) corresponding to the direct repeat (DR) region of
the genome of Mycobacterium tuberculosis according to
the procedure described by Kamerbeek et al. Amplifica-
tion and hybridization were performed using an in house
prepared membrane [16]. The hybridized membrane was
exposed to X-ray film for detection of hybridization
signal. The X-ray film (Hyperfilm™ ECL, Amersham Bio-
science UK Ltd.) was read manually to obtain a complete
pattern of the presence or absence of the spacers be-
tween the Direct Repeats harboured by a particular
strain. To determine the spoligotype family, patterns
were compared to those in the international database of
Spoligo patterns (SpolDB4).
MIRU-VNTR
MIRU-VNTR is a PCR-based typing method that assigns
the number of tandem repeats for independent loci
(MIRUs) that were found to be polymorphic in MTB.
Standardized MIRU-VNTR typing based on 15 loci was
performed using the manual method. Each locus was
amplified separately by simplex PCR with Qiagen Hotstart
Taq Polymerase kit including Q solution, according to the
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Genotyping of MTB Technical Guide [17]. Products were
analyzed by electrophoresis using 2% agarose (Promega,
Fitchburg, USA) gels. The H37Rv reference strain was in-
cluded in each batch of PCRs and gels.
DNA fingerprint analysis
Demographic information (sex and age), spoligotyping
and MIRU-VNTR patterns were compared to the inter-
national SpolDB4.0 database using MIRU-VNTRplus,
freely available web-based software [18]. The patterns
obtained received a spoligo-international type (SIT)
according to the cluster assignment. MIRU-VNTR pro-
files with double alleles at a single locus were considered
to be clonal variants of the same strain, whereas those
with double alleles at 2 or more loci were considered to
be mixed infections or the result of cross-contamination
[19,20]. Identical spoligotypes and MIRU-VNTR pat-
terns were considered to be in a cluster.
Data analysis
Patient data, smear, culture and DST results were en-
tered in a dedicated Access database. Quality control
was done for 20% of the fields; 100% of those with more
than 5% of mistakes and for all DST and molecular
(Spoligotyping and MIRU15 analysis) quality control was
done for the double entry of the data to the database.
Spoligotype patterns in a binary format were entered
in an Excel sheet, and compared with the spoligotype
database SpolDB4 using MIRU-VNTR plus. The Hunter
Gaston Discriminatory Index (HGDI) was used to calcu-
late the discriminatory power of spoligotyping method
[21]. The Chi square or Exact Fisher test when necessary
were employed to evaluated differences in age and drug
resistance patterns among the lineages. (Epi Info v7;
Georgia, USA). Values of p of less than 0.05 were con-
sidered significant.
Ethical consideration
The study was approved at the Institutional Review
Board at Universidad Peruana Cayetano Heredia. All en-
rolled patients signed informed consent. Data was man-
aged anonymously. Smear, culture and DST results were
given to the doctor at the health service as soon as they
were available.
Results
A total of 376 patients with a first episode of smear-
positive pulmonary TB were registered in the health fa-
cilities. For 62 patients no informed consent could be
obtained and 50 were excluded because they reported at
least one risk factor for MDR-TB. Among the 264 eli-
gible patients, 65 (24.6%) were not included because they
did not leave a sample (n = 6), the primary culture was
negative (n = 22), the subculture was negative (n = 36) or
contaminated (n = 1). Thus, the total number of cultures
from different subjects available for DNA genotyping
was 199, representing 75.4% of eligible patients for this
study. The male-to female ratio was 1.2; and median age
was 31 years (range: 18 to 78).
Drug-susceptibility test
Drug-Susceptibility Test (DST) results were available for
197 (99%) isolates. In total, 62 (31.5%) were resistant to
at least one drug and 135 (68.5%) were fully susceptible
(Table 1). Fifteen cases (7.5%) were MDR, 17 (8.6%) were
monoresistant to H, 17 (8.6%) to S, and 1 (0.5%) was re-
sistant to E (Table 1).
Distribution of different lineages
Among the 199 typed isolates, patterns from 169 (84.9%)
isolates belonged to seven lineages in the SpolDB4.0,
whereas 30 (15.1%) isolates could not be matched to any
lineage, and are thus referred to as “orphan”. Of these, 59
(34.9%) isolates belonged to the Haarlem lineage, while 110
(65.1%) were non Haarlem strains. Strains classified into non
Haarlem lineage included strains from T lineage (15.6%),
Beijing lineage (14.1%), Latin American Mediterranean
(12.6%) and U lineage (8.5%). Few isolates (4.5%) belonged
to the X and S clades (Figure 1).
Table 1 Resistance patterns of 197M. tuberculosis
complex isolates







H + S 8 (4.1)
H + E 1 (0.5)
H + S + E 3 (1.5)
MDR
H + R 5 (2.5)
H + R + S 8 (4.1)
H + R + E 1 (0.5)
H + R + S + E 1 (0.5)
Total resistant 62 (31.5)
Susceptible to all drugs 135 (68.5)
Total 197
H isoniazid, R rifampicin, S streptomycin, E ethambutol.
MDR multidrug-resistant, n number.
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Predominant spoligotypes
A total of 44 different spoligotypes (ST) were obtained
among the 199 isolates analyzed (Figure 1). Among these,
the ST50 member of the Haarlem lineage was the most
common (29.5%), followed by ST1 from the Beijing lineage
(16.5%), ST33 from the Latin American Mediterranean
lineage (7.1%) and ST53 from the T lineage (5.9%). Despite
the relatively high HGDI of 91.8% [21], spoligotyping
showed a clearly lower resolution compared to MIRU-
VNTR typing.
No correlation was found between the identified line-
ages with regard to primary drug resistance when compar-
ing MDR-TB versus non-MDRTB, non-MDR H-resistant
versus H-susceptible isolates, and any H-resistant versus
H-susceptible isolates. (see Table 2 for the most prevalent
lineage). Similarly, none of the lineages showed an associ-
ation with a specific age group, even though the Haarlem
and Beijing lineages were slightly more prevalent among
younger patients (p-value of 0.09 for Beijing and 0.07 for
Haarlem, Table 2).
MIRU-VNTR analysis
Unlike the spoligotype analysis, all isolates had a unique
MIRU-VNTR pattern and we did not observe any case
of bacterial subpopulation or mixed M. tuberculosis in-
fection among our isolates.
Discussion
Our study gives insights into the M. tuberculosis strains
circulating among patients with no known risk factors
for MDR-TB living in an area of high exposure to TB.
We found that the Haarlem lineage was present in one
third of the samples which is different from other Latin-
Figure 1 Lineage and spoligotypes prevalence among the 199 isolates of Mycobacterium tuberculosis (n = number of isolates).
Table 2 Distribution of Haarlem and Non-Haarlem strains






n = 199 n = 59 n = 140
Resistance
profile *
MDR 15 4 26.7 11 73.3 1.00
Non-MDR 182 54 29.9 128 70.1
Non-MDR
H-resistant
29 10 34.5 19 65.5 0.70
H-susceptible 168 48 28.6 120 71.4
Any H-resistant 44 14 31.8 30 68.2 0.70
H-susceptible 153 44 28.8 109 71.2
Age groups
≤ 30 years 124 31 25.0 93 75.0 0.07
> 30 years 75 28 37.3 47 62.7
*DST results were available for 197 isolates.
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American countries where the LAM lineage is the most
predominant.
There are currently six phylogeographic lineages that
make up the M. tuberculosis global population [22]. One is
the Euro-American lineage, which includes all the spoli-
gotypes predominating in the Western world (Haarlem,
LAM, and the ill-defined T group) [11]. In particular, the
Haarlem lineage is ubiquitous [23] and represents about
25% of the isolates in Europe, Central America, and the
Caribbean, suggesting a link with the post-Columbus
European colonization [24]. Haarlem strains have been re-
sponsible for a prolonged outbreak of multidrug-resistant
(MDR) tuberculosis in Argentina [23,25] and are actively
transmitted in urban settings in Colombia, causing major
public health problems [26].
Contrary to previous reports [11,22,27-30] where the
LAM lineage was the most common in Latin America,
our results demonstrated that the Haarlem lineage, and
to a lesser extent the T lineage, were the main circulat-
ing TB genotypes in patients with unknown risk factors.
The Haarlem lineage was described in the Netherlands
in 1999 [31]. Three main spoligotype-signatures define
the variants H1, H2 and H3 [32]. In our study most of
the Haarlem strains belonged to the H3-sublineage
(84.7%) and just a few belonged to the H1-sublineage
(13.6%). The Haarlem lineage is highly prevalent in
Northern Europe and also in Central Africa, where it is
believed to have been introduced during the European
colonization, but it is present in the Caribbean to a
lesser extent [33].
There are very few studies concerning the current gen-
etic epidemiology of MTB strains circulating in Peru.
Cohen et al. [34] focused on households in Lima in which
>1 MDR-TB patient received treatment between 1996 and
2004; among the 391 MDR-TB isolates from 236 persons,
the most prevalent lineages were LAM (n = 40.6%), T
(n = 33.7%), Haarlem (n = 14.0%) and Beijing (n = 6.0%).
Later on, Taype et al. [35] analyzed 323 sputum smear-
positive samples collected between 2004 - 2006 from 3
districts in the north of Lima (Rímac, San Martin de
Porres and Los Olivos districts) and found that the most
prevalent lineages were LAM (23.8%), Haarlem (23.8%),
and T (22.3%). Although the focus of these studies was
different from ours (MDR-TB in one study and different
districts in the other), and the sample size in each district
studied remained small, these data suggest a trend for an
increasing prevalence of the Haarlem genotype in the
North-Eastern area of Lima. Further studies should
focus on the emergence of the Haarlem lineage and its
possible reasons.
As spoligotyping has limited resolution we typed the
samples by 15-locus MIRU-VNTR. Interestingly, despite
that strains were obtained from patients living in an area
of high transmission, there was no evidence of a predo-
minant clone. This could be due to selection of patients
with low MDR-TB risk factors and the relatively short
time window of sampling (7 months) for analyzing re-
cent transmission [36,37].
When we stratified the genotypes by age, we observed
that 62.3% corresponds to the youngest and most pro-
ductive age group (≤30 years). Our results suggest that
the Beijing and Haarlem lineages are slightly more fre-
quent among younger people which might indicate their
recent emergence in our study population. For Beijing
this is in agreement with previous studies [38]. The ob-
served differences were not statistically significant, but
we cannot exclude that they might have been significant
if the sample size would have been larger.
The predominance of the Haarlem genotype in our
population assumes particular significance in light of
previous studies demonstrating the ability of this geno-
type to cause outbreaks of MDR-TB, as reported in
Argentina [23], the Czech Republic [39], Tunisia [40]
and Poland [41]. Compared to the country-wide Peru-
vian data, a high MDR rate was found among new
smear-positive pulmonary TB patient with unknown risk
factors for MDR living in North Lima (5.3% vs. 7.5%, re-
spectively) [4]. We also saw a high H-monoresistance
rate (8.6%) and overall high H-resistance rate (22.3%)
among the isolates, yet none of the lineages showed a sig-
nificant association with primary MDR or H resistance.
Our study has some limitations. First, since this was a
passive surveillance study, only patients attending health
care facilities at the public sector were included. Second,
the selection of patients with no known risk factors re-
lied on patient’s self-reporting, which could have masked
some risk factors, hence overestimating the MDR-TB
rates among low risk patients. Third, the absence of
clusters could be due to the relatively short study period
and the exclusion of patients with risk factors.
Conclusions
In summary, the population structure of M. tuberculosis
complex among patients with no known risk factors for
MDR-TB was diverse including 44 different spoligotypes
but none of them was related to age or to any resistance
pattern. Future prospective community-based studies
should aim to accurately estimate the genetic variability
of M. tuberculosis in high burden areas, and analyze
their relationship with MDR-TB.
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